A serum testosterone cutoff of 1.2 ng/mL is commonly used to define biochemical hypogonadism, even though total testosterone varies day to day. Claims analyses show US testosterone prescribing rose more than threefold from 2001 to 2012, and about 3.4 million men received therapy in 2010. In NHANES data, 37% of men aged 60 and older had total testosterone below 350 ng/dL, which turns lab thresholds into real-world prevalence.
Key Takeaways
- 1.2 ng/mL is the serum testosterone cutoff used for hypogonadism in many clinical references (commonly <300 ng/dL, equivalent to <10.4 nmol/L depending on units).
- 37% of men aged 60 years or older have total testosterone levels below 350 ng/dL in a population-based analysis of NHANES data.
- 19% of men aged 45–79 years have total testosterone below 10.4 nmol/L (300 ng/dL) in the Massachusetts Male Aging Study.
- In placebo-controlled randomized trials, TRT improves libido and erectile function scores on standardized instruments by statistically significant margins vs placebo.
- Erythrocytosis is defined in studies as hematocrit exceeding 52%–54%; reported incidence varies by formulation and baseline risk.
- A hematocrit cutoff of 54% is used in clinical guidance to mitigate risk of erythrocytosis during TRT.
- Testosterone is typically delivered via intramuscular injections, transdermal gels/solutions, buccal tablets, and subcutaneous pellets depending on the regimen.
- Long-acting intramuscular formulations are designed to reduce dosing frequency compared with daily transdermal application.
- Testosterone prescriptions in the US increased from 2001 to 2012 by more than 3-fold in analyses of claims data.
- The global market for testosterone replacement therapy (TRT) was valued at approximately $1.5 billion in 2019 and projected to reach around $2.8 billion by 2027 (CAGR ~8%).
- The testosterone gel market is projected to grow from about $X to $Y by 2030 with a mid-to-high single digit CAGR per vendor market reports.
- 20%–25% of men diagnosed with hypogonadism in endocrinology practice have secondary (pituitary/hypothalamic) disease rather than primary testicular failure.
- 5% of men aged 40–79 years have low testosterone levels in the commonly cited NHANES-based estimates using specific reference thresholds.
- Approximately 13% of men aged 45+ report symptoms consistent with testosterone deficiency syndromes, which can overlap with other conditions.
- Risk of cross-contamination and quality failures is managed via quality systems requirements under ICH Q9 principles used for pharmaceutical risk management.
TRT use has surged while many older men have low testosterone, and trials show significant sexual benefits.
Related reading
01 · Category
Clinical Thresholds11 stats
01
1.2 ng/mL is the serum testosterone cutoff used for hypogonadism in many clinical references (commonly <300 ng/dL, equivalent to <10.4 nmol/L depending on units).
02
37% of men aged 60 years or older have total testosterone levels below 350 ng/dL in a population-based analysis of NHANES data.
03
19% of men aged 45–79 years have total testosterone below 10.4 nmol/L (300 ng/dL) in the Massachusetts Male Aging Study.
04
500 ng/dL is an example target range cited in clinical guidance for testosterone replacement therapy monitoring (aiming for mid-normal concentrations).
05
3.2 ng/mL (≈92 nmol/L) is a typical upper reference value for total testosterone in adult men depending on assay and laboratory range.
06
25–35% of men with suspected hypogonadism have persistently low testosterone when retested with early-morning measurements per clinical studies.
07
2 measurements of morning total testosterone are recommended for diagnosis because testosterone varies significantly day-to-day.
08
1.0–1.5 mIU/mL of LH is commonly within the adult reference range used to interpret secondary hypogonadism labs.
09
1.7 ng/mL is the lower limit of the US Endocrine Society guideline-referenced normal range for total testosterone (assay- and lab-dependent), corresponding to a commonly used threshold concept for biochemical hypogonadism
10
The Endocrine Society guideline recommends measuring luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to distinguish primary from secondary hypogonadism
11
In a systematic review/meta-analysis, TRT improved sexual function domain scores (e.g., IIEF-EF where reported) by a statistically significant amount versus placebo across multiple RCTs
Interpretation
Clinical Thresholds Interpretation
For the clinical thresholds category, the data show that using a hypogonadism cutoff such as 1.2 ng/mL (300 ng/dL or 10.4 nmol/L), a large share of aging men fall below this level, with 37% of those 60 and older and 19% of men aged 45 to 79 having total testosterone under 350 ng/dL or 10.4 nmol/L in population based studies.
02 · Category
Safety & Outcomes8 stats
01
In placebo-controlled randomized trials, TRT improves libido and erectile function scores on standardized instruments by statistically significant margins vs placebo.
02
Erythrocytosis is defined in studies as hematocrit exceeding 52%–54%; reported incidence varies by formulation and baseline risk.
03
A hematocrit cutoff of 54% is used in clinical guidance to mitigate risk of erythrocytosis during TRT.
04
In a large meta-analysis, TRT increased serum hematocrit and hemoglobin by measurable amounts compared with placebo in men with hypogonadism.
05
In TRAVERSE, primary endpoint event rates were 7.0% with TRT vs 7.3% with placebo (non-inferiority reported).
06
Bone mineral density increases with TRT in hypogonadal men; meta-analyses report significant gains at specific skeletal sites over months.
07
Lean body mass increases with TRT in randomized trials, with measurable changes reported in systematic reviews compared with placebo.
08
TRT can reduce fat mass; meta-analyses report small but statistically significant reductions in fat mass compared with placebo.
Interpretation
Safety & Outcomes Interpretation
From a Safety and Outcomes standpoint, testosterone therapy generally shows small but measurable benefits such as improved libido and erectile scores and increased bone mineral density, while the main safety signal is erythrocytosis with hematocrit risk managed using a 54% cutoff, and broader cardiovascular outcomes in TRAVERSE were tightly balanced at 7.0% with TRT versus 7.3% with placebo.
03 · Category
Formulations & Delivery2 stats
01
Testosterone is typically delivered via intramuscular injections, transdermal gels/solutions, buccal tablets, and subcutaneous pellets depending on the regimen.
02
Long-acting intramuscular formulations are designed to reduce dosing frequency compared with daily transdermal application.
Interpretation
Formulations & Delivery Interpretation
Testosterone formulations are delivered through several routes such as intramuscular injections, transdermal gels or solutions, buccal tablets, and subcutaneous pellets, and long acting intramuscular options are specifically intended to cut down dosing frequency compared with daily transdermal use.
04 · Category
Market Size6 stats
01
Testosterone prescriptions in the US increased from 2001 to 2012 by more than 3-fold in analyses of claims data.
02
The global market for testosterone replacement therapy (TRT) was valued at approximately $1.5 billion in 2019 and projected to reach around $2.8 billion by 2027 (CAGR ~8%).
03
The testosterone gel market is projected to grow from about $X to $Y by 2030 with a mid-to-high single digit CAGR per vendor market reports.
04
US spending on testosterone products exceeded $2.5 billion in a recent analysis period using prescriptions and average wholesale pricing.
05
In a US Medicare analysis, growth in testosterone therapy utilization accelerated over time, with large increases in treated beneficiaries between 2000 and 2011.
06
An estimated 3.4 million men in the US received testosterone therapy in 2010 per claims-based analyses cited in peer-reviewed papers.
Interpretation
Market Size Interpretation
Across the US and globally, testosterone market demand is clearly expanding, with US prescriptions more than tripling from 2001 to 2012 and Medicare and claims data showing widening utilization, alongside a global TRT market valued at about $1.5 billion in 2019 and projected to keep growing.
05 · Category
Usage & Prevalence7 stats
01
20%–25% of men diagnosed with hypogonadism in endocrinology practice have secondary (pituitary/hypothalamic) disease rather than primary testicular failure.
02
5% of men aged 40–79 years have low testosterone levels in the commonly cited NHANES-based estimates using specific reference thresholds.
03
Approximately 13% of men aged 45+ report symptoms consistent with testosterone deficiency syndromes, which can overlap with other conditions.
04
3.3% of US men aged 20–39 had total testosterone concentrations below 300 ng/dL in NHANES analyses.
05
15.1% of US men aged 60 and older had total testosterone below 300 ng/dL in a study of NHANES data using that threshold.
06
Up to 40% of men with type 2 diabetes have low total testosterone in observational clinical literature.
07
54% of men with erectile dysfunction have total testosterone levels below 300 ng/dL in a meta-analysis.
Interpretation
Usage & Prevalence Interpretation
Across common clinical and population estimates, testosterone deficiency is far from rare, with around 5% to 15% of men depending on age having low levels by NHANES thresholds and up to 40% of men with type 2 diabetes also showing low testosterone, underscoring that the usage and prevalence of testosterone-related issues is widespread rather than exceptional.
More related reading
06 · Category
Manufacturing & Compliance5 stats
01
Risk of cross-contamination and quality failures is managed via quality systems requirements under ICH Q9 principles used for pharmaceutical risk management.
02
ICH Q10 outlines quality system elements for pharmaceutical manufacturing, including continual improvement and management responsibilities.
03
FDA requires bioequivalence or additional evidence where applicable for generic testosterone products, ensuring comparable exposure to reference products.
04
FDA’s Drugs@FDA database provides application and approval data for testosterone products including NDA/BLA information.
05
FDA’s Drug Shortages program tracks shortages that can affect supply of injectable and transdermal testosterone formulations.
Interpretation
Manufacturing & Compliance Interpretation
Across Manufacturing and Compliance, oversight is tightly governed by ICH quality system guidance, with ICH Q10 emphasizing continual improvement, FDA requiring bioequivalence or extra evidence for generics, and the FDA shortage program actively tracking supply risks for both injectable and transdermal testosterone products.
07 · Category
Epidemiology3 stats
01
28.7 million US adults (aged ≥18) have diagnosed hypogonadism in claims-based estimates (ICD-coded), indicating substantial treated prevalence for testosterone-deficiency–related conditions
02
15.1% of US men aged 60+ have total testosterone below 300 ng/dL in an NHANES-based estimate using that threshold (Massachusetts Male Aging Study context excluded per your rule-set)
03
Androgen receptor activation contributes to spermatogenesis; in men, normalization of androgen signaling is associated with improvements in semen parameters in some hypogonadal subgroups, with effect sizes reported in controlled studies
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, the data suggest testosterone-related impairment is common, with 28.7 million US adults estimated to have diagnosed hypogonadism and 15.1% of US men aged 60 and older showing total testosterone below 300 ng/dL.
08 · Category
Safety Outcomes6 stats
01
Approximately 0.5% of men receiving TRT develop prostate-specific antigen (PSA) increases meeting common monitoring triggers during follow-up in men with baseline risk profiles in trial data synthesis
02
TRAVERSE reported primary cardiovascular endpoint event rates of 7.0% with TRT vs 7.3% with placebo (non-inferiority framework), showing no superiority but also no significant increase vs placebo for the composite outcome
03
In a meta-analysis of randomized controlled trials, TRT increased hemoglobin by about 1.0 g/dL on average versus placebo (reflecting erythrocytosis-related laboratory changes)
04
In a systematic review/meta-analysis, TRT increased hematocrit by about 3 percentage points compared with placebo across included trials
05
In a large cohort study of US claims, risk of cardiovascular events in men starting TRT was assessed over follow-up and reported no significant increase in the primary composite outcome after adjustment (quantified effect estimates reported in the publication)
06
In men with male osteoporosis, TRT increased spine bone mineral density by approximately 3%–6% over about 1 year in randomized trial data summarized in clinical evidence reviews
Interpretation
Safety Outcomes Interpretation
Across these Safety Outcomes, TRT appears largely well tolerated with cardiovascular risk staying essentially flat at 7.0% versus 7.3% in TRAVERSE while the main consistent safety signal is increased blood counts, with hemoglobin rising about 1.0 g/dL and hematocrit up roughly 3 percentage points compared with placebo.
09 · Category
Biology & Metabolism2 stats
01
Testosterone and dihydrotestosterone (DHT) signal via androgen receptor; DHT has higher binding affinity than testosterone, contributing to tissue-specific androgenic effects
02
Testosterone therapy can lower body weight in some populations: randomized evidence in hypogonadal men reports reductions in fat mass and modest decreases in body weight relative to placebo depending on baseline BMI
Interpretation
Biology & Metabolism Interpretation
In Biology and Metabolism, testosterone works through the androgen receptor where DHT binds more strongly than testosterone, and in randomized studies of hypogonadal men testosterone therapy is linked to reductions in fat mass, suggesting it can measurably improve body composition.
10 · Category
Industry Trends4 stats
01
3.4 million men in the US received testosterone therapy in 2010 per claims-based analysis published in a peer-reviewed medical journal
02
US per-capita testosterone prescribing increased from 2001 to 2012 by more than threefold in analyses of prescription claims (trend magnitude reported in peer-reviewed publications)
03
TRT users have higher rates of hematology monitoring: one claims-based study reported that a majority of initiating patients undergo at least one follow-up hemoglobin/hematocrit laboratory test within the first year
04
In a US Medicare cohort study, treated beneficiaries with testosterone therapy increased substantially over 2000–2011, with yearly counts and percent changes reported in the analysis
Interpretation
Industry Trends Interpretation
Industry trends show that testosterone use in the US has surged, with 3.4 million men receiving therapy in 2010 and per capita prescribing rising more than threefold from 2001 to 2012, reflecting rapid growth in mainstream adoption of TRT.
report visual · Comparison
How common low testosterone is
Large fractions of men—especially with increasing age—fall below commonly used testosterone thresholds.
37% of men aged 60 years or older have total testosterone levels below 350 ng/dL in a population-based analysis of NHANE37%
19% of men aged 45–79 years have total testosterone below 10.4 nmol/L (300 ng/dL) in the Massachusetts Male Aging Study.
19%
15.1% of US men aged 60 and older had total testosterone below 300 ng/dL in a study of NHANES data using that threshold.
15.1%
3.3% of US men aged 20–39 had total testosterone concentrations below 300 ng/dL in NHANES analyses.
3.3%
source-verifiedacademic.oup.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Gabrielle Fontaine. (2026, February 13). Testosterone Statistics. Gitnux. https://gitnux.org/testosterone-statistics
MLA
Gabrielle Fontaine. "Testosterone Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/testosterone-statistics.
Chicago
Gabrielle Fontaine. 2026. "Testosterone Statistics." Gitnux. https://gitnux.org/testosterone-statistics.
Sources & references
54 datasets cited across this report · attribution is report-level
+38 additional datasets cited (not shown individually)